4.7 Article

Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009-2019: A Study of the National (Nationwide) Inpatient Sample

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 226, Issue SUPPL 2, Pages S154-S163

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiac120

Keywords

bronchiolitis hospitalizations; health equity; infants; Medicaid; respiratory syncytial virus; respiratory syncytial virus hospitalizations; RSV

Funding

  1. Sanofi
  2. AstraZeneca

Ask authors/readers for more resources

This study demonstrates that acute bronchiolitis due to RSV is the leading cause of hospitalizations in US infants, especially during the winter months.
Background This study describes leading causes of hospitalization, including respiratory syncytial virus (RSV), in United States infants (<1 year) from 2009 through 2019. Methods Within the National (Nationwide) Inpatient Sample (NIS) data, hospitalizations were determined by primary diagnosis using International Classification of Diseases, Ninth or Tenth Revision codes. RSV was defined as 079.6, 466.11, 480.1, B97.4, J12.1, J20.5, or J21.0. Bronchiolitis was defined as 466.19, J21.8, or J21.9. Leading causes overall and by sociodemographic variables were identified. The Kids' Inpatient Database (KID) was used for confirmatory analyses. Results Acute bronchiolitis due to RSV (code 466.11 or J21.0) was the leading primary diagnosis, accounting for 9.6% (95% confidence interval [CI], 9.4%-9.9%) and 9.3% (95% CI, 9.0%-9.6%) of total infant hospitalizations from January 2009 through September 2015 and October 2015 through December 2019, respectively; it was the leading primary diagnosis in every year accounting for >10% of total infant hospitalizations from December through March, reaching >15% in January-February. From 2009 through 2011, acute bronchiolitis due to RSV was the leading primary diagnosis in every birth month. Acute bronchiolitis due to RSV was the leading cause among all races/ethnicities, except Asian/Pacific Islanders, and all insurance payer groups. KID analyses confirmed these results. Conclusions Acute bronchiolitis due to RSV is the leading cause of US infant hospitalizations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Respiratory Syncytial Virus During the COVID-19 Pandemic Compared to Historic Levels: A Retrospective Cohort Study of a Health System

Naimisha Movva, Mina Suh, Heidi Reichert, Bradley Hintze, Mark P. Sendak, Zachary Wolf, Shannon Carr, Tom Kaminski, Meghan White, Kimberley Fisher, Charles T. Wood, Jon P. Fryzek, Christopher B. Nelson, William F. Malcolm

Summary: The research showed significant changes in the incidence of respiratory syncytial virus (RSV) respiratory infections in infants during COVID-19, with different patterns across various healthcare settings, and the emergence of interseasonal disease. It is important to continue monitoring the epidemiology of RSV to understand its impact on healthcare resources and public health policy.

JOURNAL OF INFECTIOUS DISEASES (2022)

Review Immunology

Mortality Among US Infants and Children Under 5 Years of Age with Respiratory Syncytial Virus and Bronchiolitis: A Systematic Literature Review

Lauren C. Bylsma, Mina Suh, Naimisha Movva, Jon P. Fryzek, Christopher B. Nelson

Summary: A systematic literature review was conducted to summarize the mortality rates of US infants and children aged <5 years with respiratory syncytial virus (RSV) or all-cause bronchiolitis (ACB). The study found that the reported RSV mortality rates vary greatly and there is a need for nationally representative estimates for otherwise healthy, late-preterm to full-term infants and children.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Immunology

Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019

Mina Suh, Naimisha Movva, Xiaohui Jiang, Heidi Reichert, Lauren C. Bylsma, Jon P. Fryzek, Christopher B. Nelson

Summary: This study highlights the importance of ensuring access to RSV preventive measures for all infants and reveals the rates and trends of RSV hospitalizations and emergency department visits among infants with different insurance types.

JOURNAL OF INFECTIOUS DISEASES (2022)

Review Immunology

Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life in the United States: Systematic Literature Review and Analysis( )

Elizabeth L. Glaser, Dhwani Hariharan, Diana M. Bowser, Raissa M. Gervasio, Katharine R. Rowlands, Lauren Buckley, Christopher B. Nelson, Donald S. Shepard

Summary: This study systematically reviewed and analyzed the burden of illness from respiratory syncytial virus (RSV) among infants. The results indicated that RSV reduces the quality of life of children, caregivers, and families. However, the existing data mainly focus on hospitalized premature infants, and more research is needed for full-term healthy children.

JOURNAL OF INFECTIOUS DISEASES (2022)

Review Immunology

Systematic Literature Review of Respiratory Syncytial Virus Laboratory Testing Practices and Incidence in United States Infants and Children <5 Years of Age

Naimisha Movva, Mina Suh, Lauren C. Bylsma, Jon P. Fryzek, Christopher B. Nelson

Summary: This systematic literature review examines RSV testing patterns and finds that not all infants and children with LRTI are tested for RSV, leading to an underestimation of the RSV burden in all settings.

JOURNAL OF INFECTIOUS DISEASES (2022)

Review Immunology

A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year( )

Mina Suh, Naimisha Movva, Lauren C. Bylsma, Jon P. Fryzek, Christopher B. Nelson

Summary: A systematic review of studies on respiratory syncytial virus (RSV) and bronchiolitis in US infants revealed substantial variability in the burden and healthcare utilization rates. Nationally representative studies are needed to understand the impact of RSV and healthcare utilization.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Immunology

All Infants Are at Risk of Developing Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection and Deserve Protection

Erin N. Hodges, Meghan White, Christopher B. Nelson

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Immunology

Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020

Jason R. Gantenberg, Robertus van Aalst, Nicole Zimmerman, Brendan Limone, Sandra S. Chaves, William V. La Via, Christopher B. Nelson, Christopher Rizzo, David A. Savitz, Andrew R. Zullo

Summary: RSV is a major cause of infant hospitalization in the United States. While preterm infants and those with specific comorbidities are at high risk, 80% of RSV infections occur in term infants without comorbidities. Future prevention efforts should target all infants.

JOURNAL OF INFECTIOUS DISEASES (2022)

Review Immunology

Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis

Diana M. Bowser, Katharine R. Rowlands, Dhwani Hariharan, Raissa M. Gervasio, Lauren Buckley, Yara Halasa-Rappel, Elizabeth L. Glaser, Christopher B. Nelson, Donald S. Shepard

Summary: This study examines the economic costs of respiratory syncytial virus (RSV) infections among infants and young children in the United States. The findings suggest that public sources bear the majority of the medical costs associated with infants' RSV treatment, and full-term infants account for the majority of RSV hospitalizations and costs.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Public, Environmental & Occupational Health

Quality of life burden on United States infants and caregivers due to lower respiratory tract infection and adjusting for selective testing: Pilot prospective observational study

Dhwani Hariharan, V. S. Senthil Kumar, Elizabeth L. Glaser, William H. Crown, Zachary A. Wolf, Kimberley A. Fisher, Charles T. Wood, William F. Malcolm, Christopher B. Nelson, Donald S. Shepard

Summary: This study estimates the quality of life for healthy US infants with RSV-LRTI and their caregivers and corrects for selective testing. It found that the quality of life for RSV-LRTI patients was significantly lower, and this loss was also present in outpatient cases.

HEALTH SCIENCE REPORTS (2023)

Review Health Care Sciences & Services

Scoping Review of Employer-Led Research Using Employee Health Claims Data

Naimisha Movva, Susan T. Pastula, Saumitra V. Rege, R. Jeffrey Lewis, Lauren C. Bylsma

Summary: This scoping review investigates the use of employee health claims data by self-insured employers. The study findings show that these data can be utilized to assess the effectiveness of medical insurance and wellness plans, monitor employee health trends, and identify measures to improve employee health and reduce absenteeism.

POPULATION HEALTH MANAGEMENT (2023)

Review Oncology

Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer

Lauren C. Bylsma, Xerxes Pundole, Chia-Hsin Ju, Naushin Hooda, Naimisha Movva, Ehab Elkhouly, Gwyn Bebb, Jon Fryzek, Pablo Martinez, Akhila Balasubramanian, Anne-Marie C. Dingemans

Summary: DLL3 expression is highly prevalent in SCLC, but further research and analytical methods are needed to determine if there are any differences in patient survival or treatment response based on DLL3 expression in SCLC.

TARGETED ONCOLOGY (2023)

Article Immunology

Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US)

Christopher B. Nelson, Brenna L. Brady, Megan Richards, Carolyn R. Lew, William La Via, Michael Greenberg, Christopher Rizzo

Summary: The objective of this study was to assess the time from birth hospitalization discharge to the first outpatient visit (FOV) among US infants in order to determine optimal site of administration for the extended half-life antibody. The results found that Medicaid infants had a significantly lower completion rate of FOV compared to commercially insured infants. For US infants born during the RSV season, administration of extended half-life RSV antibodies in the newborn nursery prior to discharge would ensure optimal uptake and minimize access disparities.

VACCINE (2023)

Article Immunology

Mortality Associated With Respiratory Syncytial Virus, Bronchiolitis, and Influenza Among Infants in the United States: A Birth Cohort Study From 1999 to 2018

Heidi Reichert, Mina Suh, Xiaohui Jiang, Naimisha Movva, Lauren C. Bylsma, Jon P. Fryzek, Christopher B. Nelson

Summary: This study describes the mortality rate of infants in the United States due to respiratory syncytial virus (RSV). The highest mortality rates were observed among infants with a gestational age of less than 29 weeks, American Indian/Alaskan Native infants, and Medicaid-insured infants. However, the burden of RSV mortality was greatest in full-term infants, white infants, and Medicaid-insured infants.

JOURNAL OF INFECTIOUS DISEASES (2022)

No Data Available